A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)
Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients
Objective: To compare the correlation with some assessments of DAT scan and myocardial MIBG scintigraphy between depression and anhedonia in drug naive Parkinson's Disease (PD)…Entity of excessive daytime sleepiness in Parkinson’s disease
Objective: To examine frequency and reasons of excessive daytime sleepiness (EDS) in patients with Parkinson’s disease (PD). Background: Neurodegeneration and dopaminergic medications are known to…Prevalence and factors related to orthostatic hypotension and orthostatic intolerance in recently-diagnosed, drug-naïve Parkinson’s disease patients
Objective: To explore the prevalence and factors related to orthostatic hypotension (OH) and orthostatic intolerance (OI) in recently diagnosed drug-naïve PD patients from the Parkinson’s…Alterations of Blood Pressure Circadian Rhythm in Alpha-Synucleinopathies
Objective: To analyze the blood pressure (BP) circadian rhythm in Parkinson’s disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF), evaluating possible differences…The prevalence of supine hypertension and nocturnal hypertension and the difference of blood pressure in each sleep position in Parkinson’s disease
Objective: This study aimed to determine the prevalence, associated factors of SH/NH and to identify relationships between blood pressure (BP) and sleep position in PD…Decreased baroreflex sensitivity in Parkinson’s disease is associated with orthostatic hypotension
Objective: To compare the baroreflex sensitivity (BRS) of Parkinson’s disease patients with those of an age-matched control population, and to determine BRS association with blood pressure,…Heart Rate Variability and Cognitive Impairment in Parkinson’s Disease
Objective: To evaluate the association between the heart rate variability (HRV) and cognitive impairment in PD patients. Background: Emerging evidence suggests an association between cognitive…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- Next Page »